U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07611838) titled 'Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction' on May 21.
Brief Summary: To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.
Study Start Date: Jan. 01, 2021
Study Type: OBSERVATIONAL
Condition:
Allergic Bronchopulmonary Aspergillosis (ABPA)
Machine Learning
Multi-omics
Multicenter Study
Relapse
Recruitment Status: RECRUITING
Sponsor: Qianfoshan Hospital
Information provided by (Responsible Party): Qian Qi, Qianfoshan Hospital
Disclaimer:...